Hengrui Medicine gets green light for SHR-9803 clinical trials

Jiangsu Hengrui Medicine (SSE:600276) announced it has received approval from the National Medical Products Administration (NMPA) for clinical trials of its injectable drug, SHR-9803. The drug, a Class 1 therapeutic biological product, will be evaluated in patients with advanced solid tumors. SHR-9803 is designed to activate anti-tumor immunity by targeting and clearing regulatory T cells (Tregs) within the tumor microenvironment, aiming for enhanced safety and efficacy. Currently, there are no similar drugs approved for the market. As of now, Hengrui Medicine has invested approximately RMB 10.74 million in the SHR-9803 project. While this approval is a positive step, the company cautions investors that the drug's development and commercialization are subject to various uncertainties and risks. Hengrui will actively advance the project.